| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Gamunex - C vs HyQvia
Side-by-side clinical, coverage, and cost comparison for polyradiculoneuropathy, chronic inflammatory demyelinating.Deep comparison between: Gamunex-C vs Hyqvia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHyqvia has a higher rate of injection site reactions vs Gamunex-C based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Hyqvia but not Gamunex-C, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gamunex-C
Hyqvia
At A Glance
IV infusion / SC injection
Every 3-4 weeks
Immune globulin
SC injection
Every 3-4 weeks
Immune globulin (IgG replacement)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Congenital agammaglobulinemia
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency, Congenital agammaglobulinemia IV: 300-600 mg/kg every 3-4 weeks; SC: initial weekly dose = prior monthly IGIV dose (g) x 1.37 divided by the number of weeks between IV doses, adjusted based on clinical response and IgG trough levels.
Immune thrombocytopenic purpura IV only: total dose of 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV loading dose: 2 g/kg over 2-4 consecutive days; maintenance: 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300 to 600 mg/kg SC every 3 to 4 weeks after initial ramp-up from 1-week to full dose; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose at each infusion site.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Same dose and frequency as prior IGIV treatment SC, typical dosing interval 4 weeks; rHuPH20 at 80 U/g IgG infused immediately before each IgG dose; ramp-up recommended based on tolerability.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity reaction
- History of anaphylactic or severe systemic reactions to IgG administration
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- Known systemic hypersensitivity to hyaluronidase including rHuPH20
- Known systemic hypersensitivity to human albumin (in the hyaluronidase solution)
Adverse Reactions
Most common (>=5%) Headache, pyrexia, nausea, cough, rhinitis, pharyngitis, asthma, diarrhea, sinusitis, vomiting, ecchymosis, rash, arthralgia, chills, hypertension, asthenia, fatigue, local infusion site reactions (SC administration), upper respiratory tract infection, back pain, dyspepsia, abdominal pain.
Serious Exacerbation of autoimmune pure red cell aplasia, pulmonary embolism, hemolytic anemia.
Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, acute respiratory distress syndrome, TRALI, pulmonary edema, bronchospasm, cardiac arrest, thromboembolism, vascular collapse, coma, seizures, aseptic meningitis, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, pancytopenia, leukopenia, hemolytic anemia, hepatic dysfunction.
Most common (>5%) Local infusion site reactions (discomfort/pain, erythema, swelling/edema, pruritus), headache, fatigue, nausea, pyrexia, vomiting
Postmarketing Hypersensitivity, influenza-like illness, infusion site leaking, anaphylactic reaction, tremor, tachycardia, hypotension, infusion related reaction, dyspnea, paresthesia oral, dermatitis allergic, injection site rash, alanine aminotransferase increased
Pharmacology
GAMUNEX-C supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanisms of action in ITP and CIDP have not been fully elucidated.
Immune globulin (IgG) replacement product in which the Immune Globulin Infusion (Human), 10% supplies broad-spectrum opsonizing and neutralizing IgG antibodies against bacterial and viral agents, while rHuPH20 transiently depolymerizes subcutaneous hyaluronan to increase tissue permeability, facilitating dispersion and absorption of the full IgG dose administered subcutaneously.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gamunex-C
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (7/12) · Qty limit (0/12)
Hyqvia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Gamunex-C
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Hyqvia
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Gamunex-C
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Hyqvia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gamunex-C.
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Gamunex-CView full Gamunex-C profile
HyqviaView full Hyqvia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.